盐酸埃克替尼和细胞因子诱导的杀伤细胞对肺腺癌细胞的体外杀伤作用研究
目的探讨盐酸埃克替尼（icotinib）和细胞因子诱导的杀伤细胞（CIK）对人肺腺癌细胞的体外抑制作用。方法采用CCK－8法检测icotinib和CIK对HCC827和A549细胞的抑制作用，应用Annexin V－FITC/PI双染法检测肿瘤细胞凋亡，流式细胞仪分析icotinib作用CIK表型的变化。结果1.5、3、6、12 μmol/L icotinib对HCC827细胞的抑制率分别为（5.64±0.05）%、（8.62±0.45）%、（14.57±0.65）%和（18.52±0.91）%，对A549细胞的抑制率分别为（1.64±0.48）%、（2.09±0.28）%、（3.69±0.4...
Saved in:
| Published in | 中华肿瘤杂志 Vol. 39; no. 8; pp. 573 - 578 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
山西医学科学院山西大医院肿瘤内二科, 太原,030032
2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0253-3766 |
| DOI | 10.3760/cma.j.issn.0253-3766.2017.08.003 |
Cover
| Abstract | 目的探讨盐酸埃克替尼（icotinib）和细胞因子诱导的杀伤细胞（CIK）对人肺腺癌细胞的体外抑制作用。方法采用CCK－8法检测icotinib和CIK对HCC827和A549细胞的抑制作用，应用Annexin V－FITC/PI双染法检测肿瘤细胞凋亡，流式细胞仪分析icotinib作用CIK表型的变化。结果1.5、3、6、12 μmol/L icotinib对HCC827细胞的抑制率分别为（5.64±0.05）%、（8.62±0.45）%、（14.57±0.65）%和（18.52±0.91）%，对A549细胞的抑制率分别为（1.64±0.48）%、（2.09±0.28）%、（3.69±0.45）%和（4.41±0.58）%。在相同浓度下，icotinib对HCC827细胞的抑制率明显高于A549细胞（P〈0.05）。效靶比为10∶1、20∶1、40∶1时，CIK对HCC827细胞的抑制率分别为（15.17±2.33）%、（42.59±7.18）%和（62.59±8.95）%，对A549细胞的抑制率分别为（16.99±2.81）%、（46.31±1.89）%和（58.24±4.23）%，相同效靶比的CIK对HCC827和A549细胞的抑制率差异无统计学意义（P10∶1＝0.299，P20∶1＝0.318，P40∶1＝0.366）。6 μmol/L icotinib联合CIK后，在10∶1、20∶1、40∶1效靶比下，对HCC827细胞的抑制率分别为（37.07±3.50）%、（76.03±6.55）%和（80.34±10.69）%，对A549细胞的抑制率分别为（25.72±1.41）%、（52.76±3.82）%和（62.26±1.94）%，除6 μmol/L icotinib＋40∶1 CIK组与40∶1 CIK组对A549细胞的抑制率差异无统计学意义外（P＝0.089），其他各联合组对肿瘤细胞的抑制率明显高于icotinib组和相同效靶比下CIK组（P〈0.05），且联合组CI值均〈1。联合组的HCC827和A549细胞凋亡率明显高于icotinib组和空白对照组（P〈0.05），晚期凋亡或坏死细胞比例显著上升，随着CIK效靶比的升高，其抑制作用更强（P〈0.05）。icotinib作用前后的CIK表型表达率差异无统计学意义（P〉0.05）。结论icotinib对表皮生长因子受体（EGFR）突变型肺腺癌细胞更 |
|---|---|
| AbstractList | 目的 探讨盐酸埃克替尼(icotinib)和细胞因子诱导的杀伤细胞(CIK)对人肺腺癌细胞的体外抑制作用. 方法 采用CCK-8法检测icotinib和CIK对HCC827和A549细胞的抑制作用,应用Annexin V-FITC/PI双染法检测肿瘤细胞凋亡,流式细胞仪分析icotinib作用CIK表型的变化. 结果 1.5、3、6、12 μmol/L icotinib对HCC827细胞的抑制率分别为(5.64±0.05)%、(8.62±0.45)%、(14.57±0.65)%和(18.52±0.91)%,对A549细胞的抑制率分别为(1.64±0.48)%、(2.09±0.28)%、(3.69±0.45)%和(4.41±0.58)%.在相同浓度下,icotinib对HCC827细胞的抑制率明显高于A549细胞(P<0.05).效靶比为10∶1、20∶1、40∶1时,CIK对HCC827细胞的抑制率分别为(15.17±2.33)%、(42.59±7.18)%和(62.59±8.95)%,对A549细胞的抑制率分别为(16.99±2.81)%、(46.31±1.89)%和(58.24±4.23)%,相同效靶比的CIK对HCC827和A549细胞的抑制率差异无统计学意义(P10∶1=0.299,P20∶1=0.318,P40∶1=0.366).6 μmol/L icotinib联合CIK后,在10∶1、20∶1、40∶1效靶比下,对HCC827细胞的抑制率分别为(37.07±3.50)%、(76.03±6.55)%和(80.34±10.69)%,对A549细胞的抑制率分别为(25.72±1.41)%、(52.76±3.82)%和(62.26±1.94)%,除6 μmol/L icotinib+40∶1 CIK 组与40∶1 CIK 组对A549细胞的抑制率差异无统计学意义外(P=0.089),其他各联合组对肿瘤细胞的抑制率明显高于icotinib组和相同效靶比下CIK组(P<0.05),且联合组CI值均<1.联合组的HCC827和A549细胞凋亡率明显高于icotinib组和空白对照组(P<0.05),晚期凋亡或坏死细胞比例显著上升,随着CIK效靶比的升高,其抑制作用更强(P<0.05).icotinib作用前后的CIK表型表达率差异无统计学意义(P>0.05). 结论 icotinib对表皮生长因子受体(EGFR) 目的探讨盐酸埃克替尼（icotinib）和细胞因子诱导的杀伤细胞（CIK）对人肺腺癌细胞的体外抑制作用。方法采用CCK－8法检测icotinib和CIK对HCC827和A549细胞的抑制作用，应用Annexin V－FITC/PI双染法检测肿瘤细胞凋亡，流式细胞仪分析icotinib作用CIK表型的变化。结果1.5、3、6、12 μmol/L icotinib对HCC827细胞的抑制率分别为（5.64±0.05）%、（8.62±0.45）%、（14.57±0.65）%和（18.52±0.91）%，对A549细胞的抑制率分别为（1.64±0.48）%、（2.09±0.28）%、（3.69±0.45）%和（4.41±0.58）%。在相同浓度下，icotinib对HCC827细胞的抑制率明显高于A549细胞（P〈0.05）。效靶比为10∶1、20∶1、40∶1时，CIK对HCC827细胞的抑制率分别为（15.17±2.33）%、（42.59±7.18）%和（62.59±8.95）%，对A549细胞的抑制率分别为（16.99±2.81）%、（46.31±1.89）%和（58.24±4.23）%，相同效靶比的CIK对HCC827和A549细胞的抑制率差异无统计学意义（P10∶1＝0.299，P20∶1＝0.318，P40∶1＝0.366）。6 μmol/L icotinib联合CIK后，在10∶1、20∶1、40∶1效靶比下，对HCC827细胞的抑制率分别为（37.07±3.50）%、（76.03±6.55）%和（80.34±10.69）%，对A549细胞的抑制率分别为（25.72±1.41）%、（52.76±3.82）%和（62.26±1.94）%，除6 μmol/L icotinib＋40∶1 CIK组与40∶1 CIK组对A549细胞的抑制率差异无统计学意义外（P＝0.089），其他各联合组对肿瘤细胞的抑制率明显高于icotinib组和相同效靶比下CIK组（P〈0.05），且联合组CI值均〈1。联合组的HCC827和A549细胞凋亡率明显高于icotinib组和空白对照组（P〈0.05），晚期凋亡或坏死细胞比例显著上升，随着CIK效靶比的升高，其抑制作用更强（P〈0.05）。icotinib作用前后的CIK表型表达率差异无统计学意义（P〉0.05）。结论icotinib对表皮生长因子受体（EGFR）突变型肺腺癌细胞更 |
| Abstract_FL | Objective To explore the inhibitory effect of icotinib combined with cytokine induced killer (CIK) on various human lung adenocarcinoma cell lines in vitro.Methods The inhibitory effect of icotinib alone or icotinib combined with CIK on HCC827 and A549 cells was detected by cell counting kit-8(CCK-8).The apoptosis was detected by flow cytometry via Annexin V/PI staining.The effect of icotinib on CIK phenotype was detected by flow cytometry.Results The inhibitory rates of HCC827 cells treated with 1.5, 3, 6, 12 μmol/L icotinib were (5.64±0.05)%, (8.62±0.45)%, (14.57±0.65)% and (18.52±0.91)%, respectively.The inhibitory rates of A549 cells were (1.64±0.48)%, (2.09±0.28)%, (3.69±0.45)%,(4.41±0.58)%, respectively.At the same concentration, the inhibitory rate of HCC827 cells with icotinib treatment was significantly higher than that of A549 cells (P<0.05).When the effector/target ratio was 10∶1, 20∶1 or 40∶1, the inhibitory rates of HCC827 cells co-cultured with CIK were (15.17±2.33)%, (42.59±7.18)%, (62.59±8.95)%, respectively, and the inhibitory rates of A549 were(16.99±2.81)%, (46.31±1.89)%, (58.24±4.23)%, respectively.The inhibitory rate of HCC827 cells co-cultured with CIK was not significantly different from that of A549 cells at the same effector/target ratio (P10∶1=0.299, P20∶1=0.318, P40∶1=0.366).When the effector/target ratio of CIK combined with 6 μmol/L icotinib was 10∶1, 20∶1 or 40∶1, the inhibitory rates of HCC827 cells were (37.07±3.50)%, (76.03±6.55)%, (80.34±10.69)%,respectively, and the inhibitory rates of A549 cells were(25.72±1.41)%, (52.76±3.82)%,(62.26±1.94)%,respectively.The inhibitory rates of 6 μmol/L icotinib combined with CIK were significantly higher than those of icotinib group and CIK group alone at the same effector/target ratio (P<0.05), except for the effector/target ratio at 40∶1 on A549 cells (P=0.089).Moreover, all of the combination index (CI) of combined group were <1 (P<0.05).The apoptotic rates of HCC827 and A549 cells induced by icotinib combined with CIK were significantly higher than those of icotinib group and blank control group (P<0.05), especially the proportion of late apoptotic or necrotic cells.Increasing effector/target ratio of CIK contributed to stronger inhibition(P<0.05).The expressional rate of CIK phenotype with or without icotinib treatment was not significantly different from each other(P>0.05).Conclusions EGFR mutant lung adenocarcinoma cells are more sensitive to icotinib, while the EGFR mutation status has no effect on the killing effect of CIK cells.icotinib combined with CIK has a synergistic effect on the inhibition of tumor growth, and icotinib has no any impact on the phenotype of CIK cells. |
| Author | 姚冰清 贾原 郭继强 赵晴 孙虎 张俊萍 |
| AuthorAffiliation | 山西医学科学院山西大医院肿瘤内二科,太原030032 |
| AuthorAffiliation_xml | – name: 山西医学科学院山西大医院肿瘤内二科, 太原,030032 |
| Author_FL | Yao Bingqing Sun Hu Zhao Qing Guo Jiqiang Zhang Junping Jia Yuan |
| Author_FL_xml | – sequence: 1 fullname: Yao Bingqing – sequence: 2 fullname: Jia Yuan – sequence: 3 fullname: Guo Jiqiang – sequence: 4 fullname: Zhao Qing – sequence: 5 fullname: Sun Hu – sequence: 6 fullname: Zhang Junping |
| Author_xml | – sequence: 1 fullname: 姚冰清 贾原 郭继强 赵晴 孙虎 张俊萍 |
| BookMark | eNo90E1LAlEUBuC7MMjMPxEEbWa6M_fTZUhfILRxL9c7MzqiYzlE5Coy3dRCSoKyDxcuahHWJsqU_ozXmf5FE0qrA-95OAfeJRDzqp4NwJoBdcQoXJcVoZd01_c9HZoEaVFIdRMaTIdchxDFQPw_XwRJ33fzkBiIcmTQOJBBt_3T_FCPDdU8n3a_1etIXV4EX62w8aC6PfXSDgdvajAKbs-m9yeTUX--GnyGp8OwOQxu5jgCk_GV6l_P2GR8F3Segl4neH5fBguOKPt2cj4TILu1mU3vaJm97d30RkaThCEt5RCBLcjsFMXYtiQ0sUN5HiMLS8u0JBEOkkQKyKBtYMwENYiEHCNqY2RyihJgdXb2SHiO8Aq5UvWw5kUPc_VivfzXCORRH5FbmTlZrHqFAzeS-zW3ImrHOcpMzlImRegXXbeKyw |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3760/cma.j.issn.0253-3766.2017.08.003 |
| DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Killing effect of icotinib combined with CIK on human lung adenocarcinoma cells in vitro |
| DocumentTitle_FL | Killing effect of icotinib combined with CIK on human lung adenocarcinoma cells in vitro |
| EndPage | 578 |
| ExternalDocumentID | zhzl201708003 672879263 |
| GrantInformation_xml | – fundername: 山西省生物治疗基础建设示范平台(2014091105-0101)Fund program: Demonstration Platform of Biological Treatment Infrastructure Construction in Shanxi Province funderid: (2014091105-0101) |
| GroupedDBID | --- -05 123 2B. 2C~ 2RA 92F 92I 92L ABDBF ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP CW9 EOJEC OBODZ TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI ACUHS PSX |
| ID | FETCH-LOGICAL-c573-9f5a4d07e9644edc024f68b43d4cd2dc5af3c5ca070e1447a615c08436e432863 |
| ISSN | 0253-3766 |
| IngestDate | Thu May 29 04:00:01 EDT 2025 Wed Feb 14 09:59:36 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 8 |
| Keywords | 细胞凋亡 Icotinib 细胞因子诱导的杀伤细胞 盐酸埃克替尼 Cytokine induced killer 肺肿瘤 Lung neoplasms Apoptosis |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c573-9f5a4d07e9644edc024f68b43d4cd2dc5af3c5ca070e1447a615c08436e432863 |
| Notes | ObjectiveTo explore the inhibitory effect of icotinib combined with cytokine induced killer （CIK） on various human lung adenocarcinoma cell lines in vitro.MethodsThe inhibitory effect of icotinib alone or icotinib combined with CIK on HCC827 and A549 cells was detected by cell counting kit-8（CCK-8）. The apoptosis was detected by flow cytometry via Annexin V/PI staining. The effect of icotinib on CIK phenotype was detected by flow cytometry.ResultsThe inhibitory rates of HCC827 cells treated with 1.5, 3, 6, 12 μmol/L icotinib were （5.64±0.05）%, （8.62±0.45）%, （14.57±0.65）% and （18.52±0.91）%, respectively. The inhibitory rates of A549 cells were （1.64±0.48）%, （2.09±0.28）%, （3.69±0.45）%, （4.41±0.58）%, respectively. At the same concentration, the inhibitory rate of HCC827 cells with icotinib treatment was significantly higher than that of A549 cells （P〈0.05）. When the effector/target ratio was 10∶1, 20∶1 or 40∶1, the inhibitory rates of HCC827 cells co-cultured with CIK were （15.17±2.33）%, （42.59±7.18）%, （62.59±8. |
| PageCount | 6 |
| ParticipantIDs | wanfang_journals_zhzl201708003 chongqing_primary_672879263 |
| PublicationCentury | 2000 |
| PublicationDate | 2017 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – year: 2017 text: 2017 |
| PublicationDecade | 2010 |
| PublicationTitle | 中华肿瘤杂志 |
| PublicationTitleAlternate | Chinese Journal of Oncology |
| PublicationTitle_FL | Chinese Journal of Oncology |
| PublicationYear | 2017 |
| Publisher | 山西医学科学院山西大医院肿瘤内二科, 太原,030032 |
| Publisher_xml | – name: 山西医学科学院山西大医院肿瘤内二科, 太原,030032 |
| SSID | ssib051368316 ssib007279245 ssib000995398 ssj0042033 ssib017477325 ssib006576341 ssib001103529 ssib058574917 |
| Score | 2.1477892 |
| Snippet | 目的探讨盐酸埃克替尼（icotinib）和细胞因子诱导的杀伤细胞（CIK）对人肺腺癌细胞的体外抑制作用。方法采用CCK－8法检测icotinib和CIK对HCC827和A549细胞的抑制作用，应... 目的 探讨盐酸埃克替尼(icotinib)和细胞因子诱导的杀伤细胞(CIK)对人肺腺癌细胞的体外抑制作用. 方法 采用CCK-8法检测icotinib和CIK对HCC827和A549细胞的抑制作用,应... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 573 |
| SubjectTerms | 盐酸埃克替尼 细胞凋亡 细胞因子诱导的杀伤细胞 肺肿瘤 |
| Title | 盐酸埃克替尼和细胞因子诱导的杀伤细胞对肺腺癌细胞的体外杀伤作用研究 |
| URI | http://lib.cqvip.com/qk/93685X/201708/672879263.html https://d.wanfangdata.com.cn/periodical/zhzl201708003 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVEBS databaseName: Academic Search Ultimate issn: 0253-3766 databaseCode: ABDBF dateStart: 20150223 customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn isFulltext: true dateEnd: 99991231 titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn omitProxy: true ssIdentifier: ssj0042033 providerName: EBSCOhost |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9RAFB_6AeJFFBVrtfTggLBszWY-MnPM7CYUQU8Veluy2WyL6NaPelk8iLVe9FC0CFo_euhBD1K9iNYW_5mmu_4XvjdJd4PUT1jCMHnze19J3nvZmQkh55xGxYuSxC1X4lajzGO3VW5EETiEVRjUbjzRAlcjX7osp6_wi7Nidmj4bnF1yWJjKu4cuK7kf7wKfeBXXCX7D57tg0IHtMG_cAQPw_GvfEwDj2pDtUMDTZWgRtFAUB1SxbABPcrQQCKNCbHHONRULY1LVRWHG0OVpIHCITqwpwz1HWz4NYusqB9SU7E9oR0OTH2quEWu4VSJgGO_zw8GxFHa9rjU-LYhbANw9C_E6LMAZBDDqgP4Wh7ENKPJBOPUV9gAFbSVx9fUyGIKbukVaocmAqhgX7bQIiiLmXFxrdFCqvvR2gpipcPREi0KtAZ1KiGOAXCrNcDqsGQdwywzqyQMRcQq6J-RC_whNxCTl_bNbs2FxglKOb2fKQyutRYEx6ha8Y1NtjQ1f6S7guEjXRbjT7aZU36fqUIwEdlHXvK8RGSfOvo55OGkJrhO4-vR1FXLZKrPBCcuenaDWocNwn1_Eqb0oFrWrmTDZNTFt1kjZNQ3NRMW0m8tittDQqoI-fog_ZVQrLJCOu3hbpSDf6mh2PU8NogXosKkYliOZJkSdx1mZ4DsC3yInM81uvAnfXArlPmF9txNSPDsert2K2rPFVLDmaPkSF7TTfrZDXqMDHXmj5O4u7byfflz-mYpXX60t_Yt_bCdPnnc_fqwt_Q6XVtP36_0Nj-mm9vdFw_2Xt3b3d7IT21-6d3f6i1vdZ_nxECwu_M03XiWke3uvOyuvu2ur3bffTpBZsJgpjpdzr9oUo7BmWXdEhFvOl6ioQpJmjHkxy2pGpw1edx0m7GIWiwWcQRhOKlw7kVQbsSO4kwmnLlKspNkpL3QTk6RSdmsxEJJESsO-aWjI-ZoTzddwATDy2iMjPftU7-RbVxT73t8jEzkFqvnj7Pb9c585xoaGEtIdvq3w8fJYaTM3kSeISOLt-4kZyE3X2xM5JfQDzYWuGA |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E7%9B%90%E9%85%B8%E5%9F%83%E5%85%8B%E6%9B%BF%E5%B0%BC%E5%92%8C%E7%BB%86%E8%83%9E%E5%9B%A0%E5%AD%90%E8%AF%B1%E5%AF%BC%E7%9A%84%E6%9D%80%E4%BC%A4%E7%BB%86%E8%83%9E%E5%AF%B9%E8%82%BA%E8%85%BA%E7%99%8C%E7%BB%86%E8%83%9E%E7%9A%84%E4%BD%93%E5%A4%96%E6%9D%80%E4%BC%A4%E4%BD%9C%E7%94%A8%E7%A0%94%E7%A9%B6&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%82%BF%E7%98%A4%E6%9D%82%E5%BF%97&rft.au=%E5%A7%9A%E5%86%B0%E6%B8%85+%E8%B4%BE%E5%8E%9F+%E9%83%AD%E7%BB%A7%E5%BC%BA+%E8%B5%B5%E6%99%B4+%E5%AD%99%E8%99%8E+%E5%BC%A0%E4%BF%8A%E8%90%8D&rft.date=2017&rft.issn=0253-3766&rft.volume=39&rft.issue=8&rft.spage=573&rft.epage=578&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-3766.2017.08.003&rft.externalDocID=672879263 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93685X%2F93685X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhzl%2Fzhzl.jpg |